Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
Mar 26, 2024 • 5:00 EDT | Read More
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
Feb 1, 2024 • 11:00 EST | Read More